Pharmaceutical use of ketoamide-based compound

Use of a class of ketoamide-based compounds, in particular, use of the ketoamide-based compound as represented by general formula A as a 2019 novel coronavirus (2019-nCov) 3CL protease inhibitor and/or human cathepsin L inhibitor in preparation of a medicament for treating and/or preventing and reli...

Full description

Saved in:
Bibliographic Details
Main Authors YANG, HAI-TAO, DAI, WEN-HAO, LIU, HONG, XU, YEUN, BAI, FANG, ZHANG, LEI-KE, JIANG, HUA-LIANG, XIE, XIONG, JIN, ZHEN-MING, CHENG, XI, CHEN, KAI-XIAN, XIAO, GENG-FU, LI, JIAN, LI, CHUN-PU, PENG, JING-JING, HU, SHU-LEI
Format Patent
LanguageChinese
English
Published 16.08.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Use of a class of ketoamide-based compounds, in particular, use of the ketoamide-based compound as represented by general formula A as a 2019 novel coronavirus (2019-nCov) 3CL protease inhibitor and/or human cathepsin L inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. The present invention also relates to use of pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection.
Bibliography:Application Number: TW202110103317